NO333073B1 - Cytotoksiske peptider modifisert med en eller flere ikke-genetiske, voluminose og/eller lipofile aminosyrer. - Google Patents

Cytotoksiske peptider modifisert med en eller flere ikke-genetiske, voluminose og/eller lipofile aminosyrer.

Info

Publication number
NO333073B1
NO333073B1 NO20010995A NO20010995A NO333073B1 NO 333073 B1 NO333073 B1 NO 333073B1 NO 20010995 A NO20010995 A NO 20010995A NO 20010995 A NO20010995 A NO 20010995A NO 333073 B1 NO333073 B1 NO 333073B1
Authority
NO
Norway
Prior art keywords
peptides
peptide
lfb
amino acids
bulky
Prior art date
Application number
NO20010995A
Other languages
English (en)
Norwegian (no)
Other versions
NO20010995D0 (no
NO20010995L (no
Inventor
John Sigurd Svendsen
Oystein Rekdal
Baldur Sveinbjornsson
Lars Vorland
Original Assignee
Lytix Biopharma As
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Lytix Biopharma As filed Critical Lytix Biopharma As
Publication of NO20010995D0 publication Critical patent/NO20010995D0/no
Publication of NO20010995L publication Critical patent/NO20010995L/no
Publication of NO333073B1 publication Critical patent/NO333073B1/no

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04Antibacterial agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/79Transferrins, e.g. lactoferrins, ovotransferrins
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Toxicology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Solid-Sorbent Or Filter-Aiding Compositions (AREA)
NO20010995A 1998-08-28 2001-02-27 Cytotoksiske peptider modifisert med en eller flere ikke-genetiske, voluminose og/eller lipofile aminosyrer. NO333073B1 (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB9818938.4A GB9818938D0 (en) 1998-08-28 1998-08-28 Bioactive peptides
PCT/GB1999/002850 WO2000012541A2 (en) 1998-08-28 1999-08-31 Cytotoxic peptides modified by bulky or lipophilic moieties

Publications (3)

Publication Number Publication Date
NO20010995D0 NO20010995D0 (no) 2001-02-27
NO20010995L NO20010995L (no) 2001-04-27
NO333073B1 true NO333073B1 (no) 2013-02-25

Family

ID=10838089

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20010995A NO333073B1 (no) 1998-08-28 2001-02-27 Cytotoksiske peptider modifisert med en eller flere ikke-genetiske, voluminose og/eller lipofile aminosyrer.

Country Status (12)

Country Link
US (3) US6890902B2 (de)
EP (2) EP1109827B1 (de)
JP (1) JP5475937B2 (de)
AT (2) ATE495192T1 (de)
AU (2) AU772176B2 (de)
CA (2) CA2340326A1 (de)
DE (1) DE69943130D1 (de)
DK (1) DK1109831T3 (de)
ES (1) ES2359616T3 (de)
GB (1) GB9818938D0 (de)
NO (1) NO333073B1 (de)
WO (2) WO2000012541A2 (de)

Families Citing this family (34)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0605685D0 (en) * 2006-03-21 2006-05-03 Lytix Biopharma As Inhibition of tumour growth
US8283315B2 (en) 1998-08-28 2012-10-09 Lytix Biopharma As Inhibition of tumour growth
GB9818938D0 (en) 1998-08-28 1998-10-21 Alpharma As Bioactive peptides
US6399570B1 (en) * 1999-02-05 2002-06-04 Agennix, Inc. Antimicrobial/endotoxin neutralizing polypeptide
GB0005702D0 (en) * 2000-03-09 2000-05-03 Alpharma As Method
GB0005703D0 (en) 2000-03-09 2000-05-03 Alpharma As Compounds
KR20020080731A (ko) * 2001-04-17 2002-10-26 주식회사 이지바이오 시스템 락토페리신 유전자 및 이를 도입한 락토페리신 발현용형질전환체
KR100454595B1 (ko) 2001-11-30 2004-10-28 주식회사 이지바이오 시스템 락토페리신 유전자 및 이를 도입한 형질전환 대장균
SE0200598D0 (sv) * 2002-02-27 2002-02-27 A & Science Invest Ab Pharmaceutical composition and method for treatment or prevention of vascular disease or states of tissue hypoperfusion with hypoxic and/or ischemic consequences
ATE519499T1 (de) * 2002-05-10 2011-08-15 Agennix Inc Lactoferrin bei der behandlung maligner neoplasien und anderer hyperproliferativer erkrankungen
US7541139B2 (en) * 2002-06-28 2009-06-02 The United States Of America As Represented By The Department Of Health And Human Services Tryptophan as a functional replacement for ADP-ribose-arginine in recombinant proteins
NO20031818D0 (no) * 2003-04-23 2003-04-23 Uni I Tromsoe Fremgangsmåte av bioaktiv peptid forberedelse
EP1635766A4 (de) * 2003-06-06 2009-09-30 Agennix Inc Lactoferrin als adjuvans in krebs-vakzinen
CN101444624B (zh) * 2004-03-19 2012-10-10 森永乳业株式会社 用于癌症治疗的药品
US8354380B2 (en) * 2004-06-17 2013-01-15 Mannkind Corporation NY-ESO-1 peptide analogs
US8034762B2 (en) 2004-09-02 2011-10-11 Cognosci, Inc. Treatment of subarachnoid hemorrhage with Apo E analogs
WO2006047744A2 (en) * 2004-10-26 2006-05-04 Agennix Incorporated Compositions of lactoferrin related peptides and uses thereof
US20090202574A1 (en) * 2004-11-19 2009-08-13 Jagat Rakesh Kanwar Methods of immune or haematological enhancement, inhibiting tumour formation or growth, and treating or preventing cancer
DE102005051366A1 (de) * 2005-10-25 2007-04-26 Degussa Gmbh Drug Delivery Systeme
WO2007055578A1 (en) * 2005-11-11 2007-05-18 Leids Universitair Medisch Centrum Cyclic antimicrobial peptides derived from lactoferrin
WO2007076904A1 (en) 2005-12-30 2007-07-12 Evonik Röhm Gmbh Peptides useful as cell-penetrating peptides
ES2321358B1 (es) * 2006-04-05 2010-03-05 Consejo Susperior De Investigaciones Cientificas Uso de peptidos derivados de la lactoferrina para preparar formulaciones inhibidoras de la enzima conversora de angiotensina i.
EP2010561A4 (de) * 2006-04-27 2010-03-24 Singapore Health Services Pte Antimikrobielle peptide
AU2007272272B2 (en) 2006-07-10 2012-04-12 Pba3 Biomed Gmbh Antimicrobial peptides
GB0821616D0 (en) 2008-11-26 2008-12-31 Lytix Biopharma As Compounds
EP2754450A1 (de) 2013-01-11 2014-07-16 Österreichische Akademie der Wissenschaften Aus Lactoferricin abgeleitete Peptide
GB201401877D0 (en) * 2014-02-04 2014-03-19 Univ Tromsoe Peptides
WO2016056665A1 (ja) * 2014-10-08 2016-04-14 学校法人慶應義塾 白血球の細胞外トラップ形成の阻害剤
ITUB20153058A1 (it) * 2015-08-11 2017-02-11 Farmagens Health Care S R L Roma ?frammento di lattoferrina per uso come agente antibatterico ed antivirale?
WO2017223098A1 (en) * 2016-06-21 2017-12-28 The Curators Of The University Of Missouri Bis-amino acid based compound and use thereof
US11174288B2 (en) 2016-12-06 2021-11-16 Northeastern University Heparin-binding cationic peptide self-assembling peptide amphiphiles useful against drug-resistant bacteria
JP7505978B2 (ja) * 2017-08-04 2024-06-25 バイオヴェンチャーズ リミテッド ライアビリティ カンパニー 線状リポペプチドパエニペプチン及びそれを使用する方法
US11236138B2 (en) * 2020-01-14 2022-02-01 Renorigin Innovation Institute Co., Ltd. Peptide, method and composition for melanin polymerization and hair darkening
CN115073352A (zh) * 2022-06-28 2022-09-20 吉尔多肽生物制药(大连市)有限公司 一种2,5,7-三叔丁基色氨酸的合成方法

Family Cites Families (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5141581A (en) * 1972-10-08 1992-08-25 Markham Harold A Implants with a cover which resists formation of firm spherical encapsulation
US4476116A (en) * 1982-12-10 1984-10-09 Syntex (U.S.A.) Inc. Polypeptides/chelating agent nasal compositions having enhanced peptide absorption
US5073542A (en) 1989-06-07 1991-12-17 Magainin Sciences Inc. CPF peptide compositions and their use in inhibiting growth of target cells or a virus
DK167813B1 (da) * 1989-12-07 1993-12-20 Carlbiotech Ltd As Pentapeptidderivat, farmaceutisk acceptable salte heraf, fremgangsmaade til fremstilling deraf og farmaceutisk praeparat indeholdende et saadant derivat
US5141851A (en) * 1990-04-18 1992-08-25 Board Of Regents, The University Of Texas System Isolated farnesyl protein transferase enzyme
JP2818056B2 (ja) * 1990-09-07 1998-10-30 森永乳業株式会社 抗菌性ペプチドおよび抗菌剤
EP0503939B1 (de) * 1991-03-13 1997-06-18 Morinaga Milk Industry Co., Ltd. Antimikrobielles Peptid und antimikrobieller Wirkstoff
WO1992022317A1 (en) * 1991-06-12 1992-12-23 Magainin Pharmaceuticals, Inc. Composition and treatment with biologically active peptides having c-terminal substitutions
US5547939A (en) * 1991-06-14 1996-08-20 The Regents Of The University Of California Broad spectrum antimicrobial compounds and methods of use
US5631228A (en) * 1991-11-01 1997-05-20 Periodontix, Inc. Anti-fungal and anti-bacterial histatin-based peptides
US5646119A (en) * 1991-11-01 1997-07-08 Periodontix, Inc. D-amino acid histatin-based peptides as anti-fungal and anti-bacterial agents
CA2128612C (en) 1992-01-23 1999-06-15 Mamoru Tomita Antimicrobial agents and method for treating products therewith
WO1993024138A1 (en) * 1992-06-01 1993-12-09 Magainin Pharmaceuticals, Inc. Biologically active peptides having n-terminal substitutions
EP1170300A1 (de) * 1992-07-13 2002-01-09 Bionebraska, Inc. Verfahren zur Modifizierung rekombinanter Polypeptide
US5593866A (en) 1992-08-21 1997-01-14 The University Of British Columbia Cationic peptides and method for production
WO1994012206A1 (en) 1992-12-03 1994-06-09 Magainin Pharmaceuticals, Inc. Treatment of dermatological malignancies with biologically active peptides
JP3312946B2 (ja) * 1993-03-04 2002-08-12 雪印乳業株式会社 ウイルス感染・増殖抑制剤
US5789542A (en) * 1994-04-22 1998-08-04 Board Of Supervisors Of Louisiana State University And Agricultural And Mechanical College Amphipathic peptides
EP0920331A1 (de) * 1996-08-12 1999-06-09 A+ Science Invest AB Behandlung und verhütung von infektionen, entzündungen und/oder tumoren mit hilfe von lactoferrin und /oder lactoferricin
CA2262429A1 (en) * 1996-08-14 1998-02-19 Novartis Ag Peptide with inhibitory activity towards plant pathogenic fungi
US6503881B2 (en) * 1996-08-21 2003-01-07 Micrologix Biotech Inc. Compositions and methods for treating infections using cationic peptides alone or in combination with antibiotics
WO1998040091A1 (en) * 1997-03-13 1998-09-17 The Research Foundation Of State University Of New York Microbicidal peptides and methods of use
GB9818938D0 (en) 1998-08-28 1998-10-21 Alpharma As Bioactive peptides

Also Published As

Publication number Publication date
WO2000012542A3 (en) 2000-06-29
AU772176B2 (en) 2004-04-08
EP1109827A2 (de) 2001-06-27
NO20010995D0 (no) 2001-02-27
US7439228B2 (en) 2008-10-21
EP1109831B1 (de) 2011-01-12
ATE513847T1 (de) 2011-07-15
NO20010995L (no) 2001-04-27
EP1109827B1 (de) 2011-06-22
DK1109831T3 (da) 2011-04-18
EP1109831A2 (de) 2001-06-27
CA2340326A1 (en) 2000-03-09
US6890902B2 (en) 2005-05-10
US8143211B2 (en) 2012-03-27
CA2341037C (en) 2013-11-05
JP2002523517A (ja) 2002-07-30
CA2341037A1 (en) 2000-03-09
ES2359616T3 (es) 2011-05-25
JP5475937B2 (ja) 2014-04-16
WO2000012541A2 (en) 2000-03-09
ATE495192T1 (de) 2011-01-15
WO2000012542A2 (en) 2000-03-09
AU5526899A (en) 2000-03-21
DE69943130D1 (de) 2011-02-24
US20080287346A1 (en) 2008-11-20
GB9818938D0 (en) 1998-10-21
WO2000012541A3 (en) 2000-06-08
US20030148936A1 (en) 2003-08-07
US20030022821A1 (en) 2003-01-30
AU5526799A (en) 2000-03-21

Similar Documents

Publication Publication Date Title
US8143211B2 (en) Bioactive peptides
Kang et al. The therapeutic applications of antimicrobial peptides (AMPs): a patent review
US9115169B2 (en) Method of treating tumors
AU2001237616A1 (en) Antimicrobial compounds and formulations
AU781243B2 (en) Methods of peptide preparation
US9109048B2 (en) Inhibition of tumor growth
US20200071357A1 (en) Antimicrobial peptides
WO2004094462A2 (en) Methods of peptide preparation
Hilchie et al. Obstacles and solutions to the use of cationic antimicrobial peptides in the treatment of cancer
Douglas Marine Flatfish-Derived Bioactive Peptides: From the Ocean to the Bedside

Legal Events

Date Code Title Description
MM1K Lapsed by not paying the annual fees